Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Fr | Tourmaline Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
27.05. | H.C. Wainwright maintains $50 target on Tourmaline Bio stock | 1 | Investing.com | ||
21.05. | Leerink raises Tourmaline Bio target to $54, affirms Outperform | 2 | Investing.com | ||
TOURMALINE BIO Aktie jetzt für 0€ handeln | |||||
21.05. | Tourmaline Bio stock holds $63 target post-Ph2 data | 3 | Investing.com | ||
21.05. | BMO maintains $35 target on Tourmaline Bio, sees overreaction | 1 | Investing.com | ||
20.05. | Tourmaline Bio shares fall on Phase 2 data; Schrödinger cuts staff | 46 | BioPharma Dive | ||
20.05. | Tourmaline Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
20.05. | Tourmaline Bio posts mid-stage data for anti-inflammatory agent | 1 | Seeking Alpha | ||
20.05. | Tourmaline Bio, Inc.: Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease | 124 | GlobeNewswire (Europe) | - Rapid, deep, and durable reductions in high-sensitivity C-reactive protein (hs-CRP) through Day 90 achieved across all pacibekitug arms with high statistical significance as compared to placebo... ► Artikel lesen | |
19.05. | Tourmaline Bio wird morgen Ergebnisse der Phase-2-Studie veröffentlichen | 1 | Investing.com Deutsch | ||
19.05. | Tourmaline Bio to reveal Phase 2 trial results tomorrow | 1 | Investing.com | ||
19.05. | Tourmaline Bio, Inc.: Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025 | 2 | GlobeNewswire (USA) | ||
02.05. | Talaris Therapeutics GAAP EPS of -$0.89 | 1 | Seeking Alpha | ||
02.05. | Tourmaline Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
02.05. | Tourmaline Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
02.05. | Tourmaline Bio, Inc.: Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights | 292 | GlobeNewswire (Europe) | - Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease remains on track for topline data readout in the second quarter 2025 - - Tourmaline... ► Artikel lesen | |
23.04. | Cantor Fitzgerald maintains Overweight on Tourmaline Bio stock | 1 | Investing.com | ||
10.04. | Truist cuts Tourmaline Bio price target to $63, maintains Buy | 2 | Investing.com | ||
14.03. | H.C. Wainwright raises Tourmaline Bio stock target to $50 | 3 | Investing.com | ||
13.03. | Tourmaline Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 95,35 | +0,05 % | Summit Therapeutics crasht - BioNTech in Sippenhaft | Wie gewonnen, so zerronnen: Die Aktie von Summit Therapeutics brach am vergangenen Freitag an der Nasdaq um rund 30 Prozent ein. Weitere Studiendaten zum großen Hoffnungsträger Ivonescimab, den die... ► Artikel lesen | |
EVOTEC | 7,060 | +0,94 % | Evotec Aktie: Ohne Übernahme sieht es schlecht aus! Auf diese Kursmarke kommt es an! | © Foto: Finanznachrichten (Symbolbild)Zwischen Kursrakete mit Übernahmefantasie und Korrekturmodus Richtung Süden. Der Biotech-Titel aus Hamburg liefert seit Wochen ein Wechselbad der Gefühle. Kann... ► Artikel lesen | |
CUREVAC | 3,830 | -0,83 % | Kauf-Alarm bei CureVac: Insider decken sich massenhaft mit Aktien ein - Das müssen Sie jetzt beachten! | ||
NOVAVAX | 6,520 | -0,20 % | Aktien New York: Rücksetzer nach US-Bonitätsabstufung verpufft | NEW YORK (dpa-AFX) - Die Abstufung der US-Kreditwürdigkeit durch Moody?s hat die Anleger in New York am Montag nicht lange beeindruckt. Benoit Anne, Anleiheexperte bei MFS Investment Management, verwies... ► Artikel lesen | |
INFLARX | 0,750 | +2,46 % | Evotec, GFT Technologies, InflaRx, Nordex, Rheinmetall, ThyssenKrupp - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
CSL | 136,82 | -1,03 % | CSL LIMITED: Notification of cessation of securities - CSL | ||
COHERUS ONCOLOGY | 0,738 | +2,08 % | Coherus BioSciences, Inc. (CHRS): A Bull Case Theory | ||
OCULAR THERAPEUTIX | 7,840 | -1,01 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | BEDFORD, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular"), a biopharmaceutical company committed to redefining the retina experience, today announced that... ► Artikel lesen | |
CYTOMX THERAPEUTICS | 2,338 | +0,34 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA (pembrolizumab) in Patients with Metastatic Melanoma | SOUTH SAN FRANCISCO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that the... ► Artikel lesen | |
ORUKA THERAPEUTICS | 10,300 | -7,21 % | Oruka Therapeutics, Inc. - 8-K, Current Report | ||
SPERO THERAPEUTICS | 2,250 | +1,35 % | Why Spero Therapeutics, Inc. (SPRO) Surged Last Week | ||
CIDARA THERAPEUTICS | 20,600 | 0,00 % | Cidara Therapeutics-Aktie behält starke Bewertung bei Citizens JMP | ||
PALVELLA THERAPEUTICS | 21,000 | -2,78 % | Palvella Therapeutics Inc.: Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update | Phase 3 SELVA trial evaluating QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs) has exceeded enrollment target of 40... ► Artikel lesen | |
NEXTCURE | 0,427 | -0,23 % | NextCure Provides Business Update and Reports Full Year 2024 Financial Results | Completed cohort 1 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers in February 2025 and plan to initiate backfill cohorts in the second half of 2025Cash of approximately $68.6 million... ► Artikel lesen | |
DIANTHUS THERAPEUTICS | 17,000 | +2,41 % | Dianthus Therapeutics, Inc.: Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results | Completed enrollment in Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) Top-line MaGic results anticipated in September 2025 to be the first of three catalysts for the DNTH103... ► Artikel lesen |